The role of tumor-associated macrophages in breast cancer progression (review)

International Journal of Oncology

Volumn 43, Issue 1, 2013, Pages 5-12

  Obeid, Elias ^a,b   Nanda, Rita ^a   Fu, Yang Xin ^b   Olopade, Olufunmilayo I ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Angiogenesis; Breast cancer; Extracellular matrix; Hypoxia; Toll like receptors; Tumor microenvironment; Tumor associated macrophges; Vascular endothelial growth factor

Indexed keywords

COLLAGEN; TOLL LIKE RECEPTOR 4; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CELL POPULATION; DISEASE FREE INTERVAL; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HYPOXIA; IMMUNE EVASION; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; METASTASIS; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; VASCULARIZATION;

BREAST NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGES; NEOPLASM METASTASIS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879654727     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1938     Document Type: Review

References (67)

1. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001. (Pubitemid 32173595)
2. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002. (Pubitemid 36019639)
3. Lewis CE, Leek R, Harris A and McGee JO: Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol 57: 747-751, 1995.
4. Bingle L, Brown NJ and Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254-265, 2002. (Pubitemid 34189413)
5. Leek RD and Harris AL: Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7: 177-189, 2002. (Pubitemid 38420774)
6. Gordon S and Taylor PR: Monocyte and macrophage heteroge neity. Nat Rev Immunol 5: 953-964, 2005.
7. Winston BW, Krein PM, Mowat C and Huang Y: Cytokine-induced macrophage differentiation: a tale of 2 genes. Clin Invest Med 22: 236-255, 1999. (Pubitemid 30119800)
8. Fujimoto H, Sangai T, Ishii G, et al: Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 125: 1276-1284, 2009.
9. Bernhagen J, Krohn R, Lue H, et al: MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13: 587-596, 2007. (Pubitemid 46828480)
10. Bando H, Matsumoto G, Bando M, et al: Expression of macro phage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 93: 389-396, 2002. (Pubitemid 34506248)
11. Hagemann T, Wilson J, Kulbe H, et al: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175: 1197-1205, 2005. (Pubitemid 41095008)
12. Mosser DM: The many faces of macrophage activation. J Leukoc Biol 73: 209-212, 2003.
13. Verreck FA, de Boer T, Langenberg DM, et al: Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 101: 4560-4565, 2004. (Pubitemid 38437450)
14. Solinas G, Germano G, Mantovani A and Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86: 1065-1073, 2009.
15. Lamagna C, Aurrand-Lions M and Imhof BA: Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 80: 705-713, 2006. (Pubitemid 44835885)
16. Benoit M, Desnues B and Mege JL: Macrophage polarization in bacterial infections. J Immunol 181: 3733-3739, 2008.
17. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati M: The chemokine system in diverse forms of macro phage activation and polarization. Trends Immunol 25: 677-686, 2004. (Pubitemid 39457982)
18. Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78, 2004.
19. Mosser DM and Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969, 2008.
20. Brown JM and Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416, 1998. (Pubitemid 28193601)
21. Vaupel P, Kelleher DK and Hockel M: Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28: 29-35, 2001. (Pubitemid 32522235)
22. Murdoch C, Giannoudis A and Lewis CE: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104: 2224-2234, 2004. (Pubitemid 39331817)
23. Turner L, Scotton C, Negus R and Balkwill F: Hypoxia inhibits macrophage migration. Eur J Immunol 29: 2280-2287, 1999. (Pubitemid 29313103)
24. Grimshaw MJ and Balkwill FR: Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - a potential mechanism. Eur J Immunol 31: 480-489, 2001. (Pubitemid 32166603)
25. Wain JH, Kirby JA and Ali S: Leucocyte chemotaxis: examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by monocyte chemoattractant proteins-1, -2, -3 and -4. Clin Exp Immunol 127: 436-444, 2002. (Pubitemid 34437815)
26. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J and Harris AL: Association of macrophage infiltration with angio genesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625-4629, 1996. (Pubitemid 26338061)
27. Burke B, Tang N, Corke KP, et al: Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 196: 204-212, 2002. (Pubitemid 34110902)
28. Kimbro KS and Simons JW: Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13: 739-749, 2006. (Pubitemid 44763255)
29. Giaccia A, Siim BG and Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2: 803-811, 2003. (Pubitemid 37361812)
30. Lewis JS, Landers RJ, Underwood JC, Harris AL and Lewis CE: Expression of vascular endothelial growth factor by macrophages is upregulated in poorly vascularized areas of breast carcinomas. J Pathol 192: 150-158, 2000.
31. Leek RD, Talks KL, Pezzella F, et al: Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 62: 1326-1329, 2002. (Pubitemid 34407787)
32. Murata Y, Ohteki T, Koyasu S and Hamuro J: IFN-gamma and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. Eur J Immunol 32: 2866-2873, 2002. (Pubitemid 35238179)
33. Doedens AL, Stockmann C, Rubinstein MP, et al: Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 70: 7465-7475, 2010.
34. Schmeisser A, Marquetant R, Illmer T, et al: The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis 178: 83-94, 2005. (Pubitemid 39600819)
35. Oda S, Oda T, Nishi K, et al: Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS One 3: e2215, 2008.
36. Yu X, Lin SG, Huang XR, et al: Macrophage migration inhibitory factor induces MMP-9 expression in macrophages via the MEK-ERK MAP kinase pathway. J Interferon Cytokine Res 27: 103-109, 2007. (Pubitemid 46294432)
37. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA and Harris AL: Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 190: 430-436, 2000. (Pubitemid 30163582)
38. Bingle L, Lewis CE, Corke KP, Reed MW and Brown NJ: Macrophages promote angiogenesis in human breast tumour spheroids in vivo. Br J Cancer 94: 101-107, 2006. (Pubitemid 43088548)
39. Vicioso L, Gonzalez FJ, Alvarez M, et al: Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer. Am J Clin Pathol 125: 111-118, 2006. (Pubitemid 43089733)
40. Lin EY, Li JF, Gnatovskiy L, et al: Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66: 11238-11246, 2006. (Pubitemid 46009952)
41. Lin EY, Li JF, Bricard G, et al: Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol 1: 288-302, 2007. (Pubitemid 350181649)
42. Ojalvo LS, King W, Cox D and Pollard JW: High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol 174: 1048-1064, 2009.
43. Tang X, Mo C, Wang Y, Wei D and Xiao H: Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 138: 93-104, 2013.
44. Nagakawa Y, Aoki T, Kasuya K, Tsuchida A and Koyanagi Y: Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 24: 169-178, 2002. (Pubitemid 34171293)
45. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62: 531-533, 1988.
46. Ulisse S, Baldini E, Sorrenti S and D'Armiento M: The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9: 32-71, 2009.
47. Kantelhardt EJ, Vetter M, Schmidt M, et al: Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel. BMC Cancer 11: 140, 2011.
48. Wyckoff JB, Wang Y, Lin EY, et al: Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67: 2649-2656, 2007. (Pubitemid 46548952)
49. Ingman WV, Wyckoff J, Gouon-Evans V, Condeelis J and Pollard JW: Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev Dyn 235: 3222-3229, 2006. (Pubitemid 44888188)
50. Rakoff-Nahoum S and Medzhitov R: Toll-like receptors and cancer. Nat Rev Cancer 9: 57-63, 2009.
51. Gonzalez-Reyes S, Marin L, Gonzalez L, et al: Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 10: 665, 2010.
52. Siednienko J and Miggin SM: Expression analysis of the Toll-like receptors in human peripheral blood mononuclear cells. Methods Mol Biol 517: 3-14, 2009.
53. Kim S, Takahashi H, Lin WW, et al: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106, 2009.
54. Naugler WE, Sakurai T, Kim S, et al: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 produc tion. Science 317: 121-124, 2007. (Pubitemid 47056470)
55. Sandholm J, Kauppila JH, Pressey C, et al: Estrogen receptor-alpha and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells. Breast Cancer Res Treat 132: 411-419, 2012.
56. Apetoh L, Ghiringhelli F, Tesniere A, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059, 2007. (Pubitemid 47517504)
57. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G and Zitvogel L: Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anti cancer therapies. Cancer Res 68: 4026-4030, 2008.
58. Kim SY, Choi YJ, Joung SM, Lee BH, Jung YS and Lee JY: Hypoxic stress upregulates the expression of Toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology 129: 516-524, 2010.
59. Tlsty TD and Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol 1: 119-150, 2006.
60. Allavena P, Signorelli M, Chieppa M, et al: Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine produc tion. Cancer Res 65: 2964-2971, 2005. (Pubitemid 40490102)
61. Dineen SP, Lynn KD, Holloway SE, et al: Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 68: 4340-4346, 2008.
62. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007.
63. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239-3247, 2010.
64. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691, 2009.
65. Green JR and Guenther A: The backbone of progress - preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 77 (Suppl 1): S3-S12, 2011.
66. Giraudo E, Inoue M and Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623-633, 2004. (Pubitemid 39578752)
67. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G and Colombo MP: Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65: 3437-3446, 2005. Institute